Literature DB >> 31437659

Nicotine effects on cognitive remediation training outcome in people with schizophrenia: A pilot study.

Britta Hahn1, Megan E Shrieves2, Marie B Yuille2, Robert W Buchanan2, Ashleigh K Wells2.   

Abstract

Cognitive remediation training can alleviate cognitive impairment associated with schizophrenia, but the impact is limited by small effect sizes. The present study aimed at augmenting training effects by administering nicotine prior to training sessions. Twenty-five people with schizophrenia were enrolled in a 10-week, 5 days/week, computerized cognitive training regimen. Participants were randomized to two treatment groups: nicotine or placebo. Every Monday and Thursday, the nicotine group received a nicotine lozenge before the training, and the placebo group a placebo lozenge. Outcome measurements were conducted on a no-lozenge day in weeks 0, 4, 7, and 10, and at 4-week follow-up. The MATRICS Consensus Cognitive Battery composite score improved over time, but there was no group difference in this effect. A significant group difference emerged over time in the reasoning/problem solving sub-domain: the placebo group improved but not the nicotine group, suggesting that nicotine exposure negatively impacted training benefits on executive control processes. There were no effects on psychiatric symptoms. However, significant improvements were seen across groups on the Quality of Life Scale and the Cognitive Assessment Interview, measuring real-life functional outcome. In conclusion, the present study failed to find evidence that nicotine exposure during cognitive remediation training may potentiate training benefits.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Cognitive remediation training; Nicotine; Schizophrenia

Mesh:

Substances:

Year:  2019        PMID: 31437659      PMCID: PMC6756954          DOI: 10.1016/j.psychres.2019.112498

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  45 in total

Review 1.  Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.

Authors:  Jason Smucny; Jason R Tregellas
Journal:  J Psychopharmacol       Date:  2017-04-26       Impact factor: 4.153

Review 2.  Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies.

Authors:  Dawn I Velligan; Robert S Kern; James M Gold
Journal:  Schizophr Bull       Date:  2006-04-26       Impact factor: 9.306

3.  A CHRNA5 allele related to nicotine addiction and schizophrenia.

Authors:  L E Hong; X Yang; I Wonodi; C A Hodgkinson; D Goldman; O C Stine; E S Stein; G K Thaker
Journal:  Genes Brain Behav       Date:  2011-04-06       Impact factor: 3.449

4.  Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.

Authors:  Deepak C D'Souza; Rajiv Radhakrishnan; Edward Perry; Savita Bhakta; Nagendra M Singh; Richa Yadav; Danielle Abi-Saab; Brian Pittman; Santosh K Chaturvedi; Mahendra P Sharma; Morris Bell; Chittaranjan Andrade
Journal:  Neuropsychopharmacology       Date:  2012-10-24       Impact factor: 7.853

5.  Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia.

Authors:  Melissa Fisher; Christine Holland; Michael M Merzenich; Sophia Vinogradov
Journal:  Am J Psychiatry       Date:  2009-05-15       Impact factor: 18.112

6.  Hearing a voice in the noise: auditory hallucinations and speech perception.

Authors:  A Vercammen; E H F de Haan; A Aleman
Journal:  Psychol Med       Date:  2007-12-13       Impact factor: 7.723

7.  Getting the cue: sensory contributions to auditory emotion recognition impairments in schizophrenia.

Authors:  David I Leitman; Petri Laukka; Patrik N Juslin; Erica Saccente; Pamela Butler; Daniel C Javitt
Journal:  Schizophr Bull       Date:  2008-09-12       Impact factor: 9.306

8.  The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls.

Authors:  Ruth S Barr; Melissa A Culhane; Lindsay E Jubelt; Rana S Mufti; Michael A Dyer; Anthony P Weiss; Thilo Deckersbach; John F Kelly; Oliver Freudenreich; Donald C Goff; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2007-04-18       Impact factor: 7.853

9.  Association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia.

Authors:  Rogerio Panizzutti; Melissa Fisher; Coleman Garrett; Wai Hong Man; Walter Sena; Caroline Madeira; Sophia Vinogradov
Journal:  Schizophr Res       Date:  2018-04-24       Impact factor: 4.939

10.  Single-Dose Bioequivalence of Two Mini Nicotine Lozenge Formulations.

Authors:  Scott C Rasmussen; William D Becker; Gilbert M Shanga
Journal:  Clin Pharmacol Drug Dev       Date:  2017-11-28
View more
  1 in total

1.  Nicotine gum enhances visual processing in healthy nonsmokers.

Authors:  Thiago P Fernandes; Natalia L Almeida; Gabriella M Silva; Natanael A Santos
Journal:  Brain Imaging Behav       Date:  2021-03-06       Impact factor: 3.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.